C+
Overall grade
B-
Financial quality
The sleeper story everyone's missing: pharma budget delays created a loaded Q4 pipeline that management can't quantify but January bookings already hit record highs. The obvious headline is AI adoption at 300K prescribers, but the real story is they're burning infrastructure costs with no monetization timeline while claiming technical superiority. The binding constraint is management's inability to price AI services - they can build it and doctors will use it, but they can't figure out how to charge for it. Most revealing quote: 'We have not included any revenue upside for AI in our current guidance' despite 20% physician adoption. My view changes if they announce specific AI pricing and launch dates in Q4, or if Anna Bryson's medical leave extends beyond next quarter.
The 30-second version
- THE SLEEPER STORY: Pharma's AI panic is hiding a customer concentration goldmine
- AI adoption at 300K prescribers looks impressive until you realize they have no monetization plan
- The CFO absence and interim arrangement screams operational stress
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Revenue | $169M (+23% YoY) | $185M (+10% YoY) |
| Adjusted EBITDA Margin | 60% | 60% |
| Free Cash Flow | $92M | $59M |
| Net Revenue Retention | 118% | 112% |
| Top 20 Customer NRR | Not disclosed | 117% |
| $500K+ Customers | 115 | 126 |
| Q4 Revenue Guidance | High-teens growth expected | 4% growth at midpoint |
| Gross Margin | 92% | 91% |
Accountability tracked
7 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →